8,425 reports of this reaction
3.0% of all DENOSUMAB reports
#4 most reported adverse reaction
OSTEONECROSIS OF JAW is the #4 most commonly reported adverse reaction for DENOSUMAB, manufactured by Amgen, Inc. There are 8,425 FDA adverse event reports linking DENOSUMAB to OSTEONECROSIS OF JAW. This represents approximately 3.0% of all 278,448 adverse event reports for this drug.
Patients taking DENOSUMAB who experience osteonecrosis of jaw should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OSTEONECROSIS OF JAW is a less commonly reported adverse event for DENOSUMAB, but still significant enough to appear in the safety profile.
In addition to osteonecrosis of jaw, the following adverse reactions have been reported for DENOSUMAB:
The following drugs have also been linked to osteonecrosis of jaw in FDA adverse event reports:
OSTEONECROSIS OF JAW has been reported as an adverse event in 8,425 FDA reports for DENOSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OSTEONECROSIS OF JAW accounts for approximately 3.0% of all adverse event reports for DENOSUMAB, making it a notable side effect.
If you experience osteonecrosis of jaw while taking DENOSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.